Your prostate cancer news “fix” for Monday, July 27th
Posted Sep 28 2008 1:49pm
In today’s prostate cancer news:
More on the effects of hormone therapy on cognitive function and
The application to market satraplatin has been withdraw in Europe
Another study has now clearly shown that hormone deprivation therapy — also known as androgen deprivation therapy or ADT — is linked to “subtle but significant cognitive decline in men with prostate cancer.” According to Reuters this study has just been published by Christian J. Nelson and colleagues in the journal Cancer. Nelson and colleagues reviewed 19 relevant studies involving animals and humans. According to their results, between 47 percent and 69 percent of ADT-treated men show impairment in one or more cognitive areas, most commonly in processes dependent on spatial ability and in high-order “executive functioning” abilities, such as the ability to multi-task. By contrast, in some studies, there was evidence that ADT may have improved verbal memory functioning. Although well designed well, most of the studies looking at the effects of ADT on cognition were small in size, Nelson and colleagues note. They call for larger studies to confirm these findings and recommend that such studies incorporate brain imaging, as has been done in analyses of the cognitive effects of chemotherapy for breast cancer.
GPC Biotech AG withdrew its application for European approval for satraplatin the treatment of prostate cancer today, dashing what few hopes remained for commercial use of the drug. “Although we previously communicated that the approval of … satraplatin would be challenging, today’s outcome is nevertheless disappointing,” GPC Chief Executive Bernd Seizinger is quoted as saying. The application covered use of the investigational chemotherapeutic agent satraplatin in combination with the steroid prednisone in hormone-refractory prostate cancer patients who had unsuccessfully been been treated with a prior chemotherapy regimen. Data from a Phase III study failed to convince an advisory panel to the US Food and Drug Administration last year.